NSCLC remains a formidable clinical challenge due to the frequent development of multidrug resistance (MDR), often driven by the overexpression of efflux transporters like ABCB1/P-glycoprotein. This evidence concerns the gene ABCB1 and non-small cell lung carcinoma.